"We are very pleased with the allowance of one of the key patents, covering the combination of apabetalone with one of the most successful statins on the market."  Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016.

 It further solidifies Resverlogix as a key player in the cardiovascular disease market," stated Donald McCaffrey, President & Chief Executive Officer.

WHAT other KEY patents are forthwith  inquiring minds want to know 

Stock2740